SCHEMBL31269094

SCHEMBL31269094

Cc1ccnc(Cn2c(-c3ccc(OCCN4CC[C@@H](O)C4)cc3Cl)nc3c(OC4(C)CC4)ncnc32)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDK2 Q15119 2/20 0.37
▸ KCNH2 Q12809 1/20 0.35
▸ SCN5A Q14524 1/20 0.35
▸ SCN9A Q15858 1/20 0.35
▸ PIK3CD O00329 4/20 0.34
▸ LTA4H P09960 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ PSEN1 P49768 1/20 0.33
▸ PSEN2 P49810 1/20 0.33
▸ APH1B Q8WW43 1/20 0.33
▸ NCSTN Q92542 1/20 0.33
▸ APH1A Q96BI3 1/20 0.33
▸ PSENEN Q9NZ42 1/20 0.33
▸ HRH4 Q9H3N8 2/20 0.32
▸ ALK Q9UM73 1/20 0.32
▸ HRH3 Q9Y5N1 1/20 0.32
▸ DRD2 P14416 2/20 0.31
▸ LRRK2 Q5S007 1/20 0.31
▸ ESR1 P03372 1/20 0.30
▸ ESR2 Q92731 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31269003 0.97 HRH4 (0.36) PDK2KCNH2SCN5ASCN9APIK3CD
SCHEMBL30983550 0.95 PDK2 (0.37) PDK2KCNH2PIK3CDLTA4HKDM4E
SCHEMBL30983862 0.94 KCNH2 (0.33) KCNH2SCN5ASCN9APIK3CDHRH4
SCHEMBL31269010 0.91 HRH3 (0.35) PDK2PIK3CDHRH4HRH3
SCHEMBL31269246 0.91 HRH3 (0.35) PDK2PIK3CDHRH4HRH3
SCHEMBL31269258 0.91 HRH4 (0.36) KCNH2SCN5ASCN9APIK3CDHRH4
SCHEMBL31269028 0.90 KCNH2 (0.37) KCNH2SCN5ASCN9APIK3CDHRH3
SCHEMBL30983391 0.90 LTA4H (0.43) PDK2KCNH2PIK3CDLTA4HKDM4E
SCHEMBL31269116 0.90 ESR1 (0.38) KDM4EHRH4DRD2ESR1ESR2
SCHEMBL31269000 0.89 PDE2A (0.39) KCNH2SCN5ASCN9APIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
Send feedback